Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

rare blood disorder

- PMLiVE

Novartis announces promising five-year data for leukaemia treatment Kymriah

Results have shown durable remission and long-term survival in children and young adults with B-cell acute lymphoblastic leukaemia

Part 4 of 4, of the Medscape video interview series

Dr. Hansa Bhargava MD interviews Dr. Maria Victoria Mateos on the most important abstracts to look out for in multiple myeloma and the potential implications of these data for managing patients...

Medscape Education Global

- PMLiVE

Novartis’ Kymriah receives FDA approval to treat follicular lymphoma

The CAR-T cell treatment is approved for adult patients who have had two or more previous therapies

- PMLiVE

EC approves Novartis’ Kymriah for advanced blood cancer

Kymriah is the first CAR-T cell therapy of its kind approved in the EU for follicular lymphoma

- PMLiVE

Novartis restructures organisation to support growth and innovation

The new operational structure will involve integrating pharmaceuticals and oncology business units into an Innovative Medicines business

- PMLiVE

Novartis’ Kesimpta trial evaluates treatment of COVID-19 in MS patients

There are an estimated 130,000 people with MS in the UK

- PMLiVE

FDA approves Novartis’ Pluvicto for prostate cancer

The treatment is the first FDA approved targeted radioligand therapy for mCRPC patients

- PMLiVE

Novartis and Voyager Therapeutics agree on gene therapy deal worth 1.7bn

The licence option agreement is for next-generation gene therapy vectors for neurological diseases

- PMLiVE

Novartis to pay up to $1.5bn for Gyroscope

The acquisition of ocular gene therapy company, Gyroscope, adds GT005 to the Novartis portfolio – a one-time gene therapy for geographic atrophy, a leading cause of blindness

- PMLiVE

Novartis strengthens links with BeiGene in a deal that could be worth up to $1bn

Novartis is to pay $300m upfront to BeiGene in a multifaceted deal to enhance its oncology portfolio and expand coverage of the Chinese market

- PMLiVE

Novartis pulls out of Mesoblast deal

Shares in Mesoblast dropped sharply after Novartis pulled out of a deal announced earlier this year to collaborate on COVID-19 medicine remestemcel-L, citing poor trial data

- PMLiVE

Roche and Novartis part ways with share purchase

Novartis is to sell its one-third stake in Roche for more than $20bn, paving the way for potential acquisitions

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links